Modern pharmacotherapy of Parkinson's disease
Authors:
- Moderní Farmakoterapie ParkinsonovyMPModerní Farmakoterapie Parkinsonovy
- Kateřina MenšíkováKMKateřina Menšíková
Open Access
- 15 July 2024
- journal article
- Published by Solen s.r.o. in Klinická farmakologie a farmacie
- Vol. 38 (2) , 60-66
Abstract
L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do... L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do...Keywords
This publication has 36 references indexed in Scilit:
- Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experienceJournal of Neural Transmission, 2023
- Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gelBrain and Behavior, 2021
- Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's DiseaseAnnals of Neurology, 2021
- Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence‐Based TherapyMovement Disorders, 2019
- EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's diseaseMovement Disorders, 2019
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine reviewMovement Disorders, 2019
- An update on adaptive deep brain stimulation in Parkinson's diseaseMovement Disorders, 2018
- Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot studyMovement Disorders, 2009
- L-DOPA: From a biologically inactive amino acid to a successful therapeutic agentAmino Acids, 2002
- Levodopa‐induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two‐year, prospective follow‐upMovement Disorders, 2002